

Supplemental Table 6. Commonly Reported TEAEs ($\geq 5\%$ of Patients in Either Group or $\geq 3\%$ of Patients With a GI Disorder) Categorized by Age Group 6 to 9 Years

System Organ Class (Preferred Term, MedDRA 19.1)	Lubiprostone 12 mcg BID (n=39), n (%)	Lubiprostone 24 mcg BID (n=3), n (%)	Total (N=42), N (%)
Patients with ≥ 1 TEAE	24 (61.5)	1 (33.3)	25 (59.5)
Gastrointestinal disorders	10 (25.6)	1 (33.3)	11 (26.2)
Nausea	4 (10.3)	1 (33.3)	5 (11.9)
Vomiting	3 (7.7)	1 (33.3)	4 (9.5)
Diarrhea	2 (5.1)	0 (0.0)	2 (4.8)
General disorders and administration site conditions	3 (7.7)	0 (0.0)	3 (7.1)
Chest pain	2 (5.1)	0 (0.0)	2 (4.8)
Infections and infestations	7 (17.9)	0 (0.0)	7 (16.7)
Gastroenteritis viral	2 (5.1)	0 (0.0)	2 (4.8)
Pharyngitis streptococcal	2 (5.1)	0 (0.0)	2 (4.8)
Sinusitis	2 (5.1)	0 (0.0)	2 (4.8)
Investigations	7 (17.9)	0 (0.0)	7 (16.7)
Blood iron decreased	3 (7.7)	0 (0.0)	3 (7.1)
Blood uric acid decreased	2 (5.1)	0 (0.0)	2 (4.8)
Nervous system disorders	2 (5.1)	0 (0.0)	2 (4.8)
Headache	2 (5.1)	0 (0.0)	2 (4.8)
Respiratory, thoracic, and mediastinal disorders	4 (10.3)	0 (0.0)	4 (9.5)
Dyspnea	2 (5.1)	0 (0.0)	2 (4.8)

BID = twice daily; GI = gastrointestinal; MedDRA = Medical Dictionary for Regulatory Activities; N = total population; n = subgroup of total population; TEAE = treatment-emergent adverse event.